Premium
Clinical Markers Predictive of Primary Inefficacy: A “Real Life” Retrospective Study in Psoriatic Patients Treated with Etanercept
Author(s) -
Giunta Alessandro,
Babino Graziella,
Manetta Sara,
Mazzotta Annamaria,
Chimenti Sergio,
Esposito Maria
Publication year - 2014
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.21206
Subject(s) - etanercept , psoriatic arthritis , medicine , psoriasis , tumor necrosis factor alpha , dermatology , immunology , pharmacology , oncology
Postmarketing Phase IVOverexpression of tumor necrosis factor alpha ( TNF ‐α) has been demonstrated to play a pivotal role in the pathogenesis of both plaque‐type psoriasis and psoriatic arthritis. TNF ‐α blockers, including etanercept, a human protein that acts as a TNF ‐α soluble receptor, are effective in the treatment of psoriasis. This retrospective study investigated the impact of psoriasis patients’ demographic and clinical characteristics on primary inefficacy to etanercept. Our findings suggest that the presence of psoriatic arthritis is a risk factor for primary inefficacy to etanercept in the treatment of psoriasis. However, etanercept efficacy appears to be independent of patient age, gender, or previous biologic treatments.